Phase III HERO Trial Finds Relugolix to be Superior to Leuprolide in Prostate Cancer

The results suggested the potential for this agent to become a new standard for T-suppression in this patient population.

Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news